Thursday, June 27, 2019 9:50:39 PM
Thank you senti I believe you put the last steps of the trial in their proper perspective. I am of course still somewhat confused but at a higher level.
I also now recall that I told DI that in the light of past attacks against NWBO I believe that the company was correct to limit its PRs to the necessary minimum so as not to give the shorts, hedge funds or whoever launch their attacks. I mentioned that I would understand if NWBO PRd nothing until top line results.
He seemed to echo and support my opinion and said something to the effect that there is no reason to signal to the enemies that there is any safe time interval that they can use for their malfeasance. He stated it somewhat different but that is the essence.
Therefore my educated guess now is that we will not hear anything until top
line. Of course I will not bet my house on it because when it comes to NWBO I have been many times more wrong than right.
I also now recall that I told DI that in the light of past attacks against NWBO I believe that the company was correct to limit its PRs to the necessary minimum so as not to give the shorts, hedge funds or whoever launch their attacks. I mentioned that I would understand if NWBO PRd nothing until top line results.
He seemed to echo and support my opinion and said something to the effect that there is no reason to signal to the enemies that there is any safe time interval that they can use for their malfeasance. He stated it somewhat different but that is the essence.
Therefore my educated guess now is that we will not hear anything until top
line. Of course I will not bet my house on it because when it comes to NWBO I have been many times more wrong than right.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
